Insights into in the metabolome of the cyanobacterium Leibleinia gracilis from the lagoon of Tahiti and first inspection of its variability

Hiren Solanki¹, Manon Pierdet², Olivier P. Thomas¹,*, and Mayalen Zubia²,*

¹ Marine Biodiscovery, School of Chemistry and Ryan Institute, National University of Ireland Galway, University Road, H91 TK33 Galway, Ireland
² UMR Ecosystèmes Insulaires Océaniens, LabEx CORAIL, University of French Polynesia, Faa’a, BP6570, 98702 Tahiti, French Polynesia

P2 Figure S1. Analytical HPLC chromatograms of the F2 fraction of L. gracilis on C18 reverse phase (UV at 210 nm and ELSD)

Figure S2. UHPLC-HRMS chromatogram and MS/MS fragmentation of the isolated major (9E)-11-oxopalmitoleic acid

P3 Figure S3. ¹H NMR of (9E)-11-oxopalmitoleic acid in CD3OD (600 MHz)

Figure S4. ¹³C NMR spectrum of (9E)-11-oxopalmitoleic acid in CD3OD (150 MHz)

P4 Figure S5. COSY spectrum of (9E)-11-oxopalmitoleic acid in CD3OD (600 MHz)

Figure S6. HSQC NMR of (9E)-11-oxopalmitoleic acid in CD3OD (600 MHz)

P5 Figure S7. HMBC NMR of (9E)-11-oxopalmitoleic acid in CD3OD (600 MHz)

P6 Figure S8. UHPLC-HRMS chromatogram showing the MS/MS fragmentation spectrum of the main annotated compound Erucamide (m/z 338.3449)

Figure S9. MS/MS fragmentation of the Erucamide: confirmation matching with Metlin database
Figure S1. Analytical HPLC chromatograms of the F2 fraction of *L. gracilis* on C18 reverse phase (UV at 210 nm and ELSD)

Figure S2. UHPLC-HRMS chromatogram and MS/MS fragmentation of the isolated major (9E)-11-oxopalmitoleic acid
Figure S3. $^1$H NMR of (9E)-11-oxopalmitoleic acid in CD$_3$OD (600 MHz)

Figure S4. $^{13}$C NMR spectrum of (9E)-11-oxopalmitoleic acid in CD$_3$OD (150 MHz)
Figure S5. COSY spectrum of (9E)-11-oxopalmitoleic acid in CD$_3$OD (600 MHz)

Figure S6. HSQC NMR of (9E)-11-oxopalmitoleic acid in CD$_3$OD (600 MHz)
Figure S7. HMBC NMR of (9E)-11-oxopalmitoleic acid in CD$_3$OD (600 MHz)
Figure S8. UHPLC-HRMS chromatogram showing the MS/MS fragmentation spectrum of the main annotated compound Erucamide (m/z 338.3449)

Figure S9. MS/MS fragmentation of the Erucamide: confirmation matching with Metlin database